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Abstract
Background
Pyrazinamide (PZA) is one of the most effective first line
treatments against tuberculosis disease. The drug generally
has bacteriostatic action. It also acts on bacterial spores
which eliminates the chances of resurfacing of the infec-
tion. However, in recent years there has been a major
increase in the occurrence of drug resistant bacterial
strains. Resistance against PZA is caused by mutations in
pyrazinamidase (PncA) protein which is the activator of
the prodrug PZA. In the present study, we have tried to
gain insights into the mechanism by which resistance
develops due to K96R mutation occurring in the PncA
catalytic region
Results
The binding cavity analysis showed an increase of 762.3
Å3 in the volume of the mutant protein. Docking studies
revealed that PZA has a greater binding affinity for the
native protein in comparison to the mutant protein.
Molecular dynamics simulations further showed the role
of flap region, which is present in PncA protein, in devel-
opment of resistance to the drug.
Conclusion
The residues of flap region acquire more flexibility in
mutant form of protein and thus move away from the
active site. This leads to weak binding of the drug to the
target residues which might interfere with the activation of
the drug to functional form thereby giving rise to drug
resistant bacterial strains.
Background
One of the major concerns being faced by the world
today is tuberculosis disease (TB). About one third of the
world population is suffering from the infection caused
by Mycobacterium tuberculosis [1]. It was estimated, that
in 2012, around 8.6 million people developed TB and
approximately 1.3 million people died because of this dis-
ease [2]. The emergence of drug-resistant bacterial
strains is one of the main causes for the current spread of
TB [3]. MDR TB or multi drug resistant tuberculosis is
caused when resistance is developed for two or more first
line drugs. Treatment of drug-resistant tuberculosis is
hampered by poor efficacy and high toxicity of the sec-
ond-line drugs [4]. Continuous efforts are being made
worldwide to find out some novel protein targets against
which new effective drugs can be designed [5,6].
Various new approaches have come up for the design-
ing of drugs for such complex diseases. One of the strate-
gies includes the development of small molecule which
could either inhibit multiple sites on the same target or
inhibit altogether different protein targets. Some previous
work done in our lab to check pathologies associated
with the Alzheimer’s disease illustrates this well. In one
of the experiments two small molecular compounds were
proposed, which had inhibitory activity against two of the
important targets associated with Alzheimer’s- b-amyloid
cleavage enzyme and acetylcholine esterase (AChE) [7].
In another work, compounds having inhibitory activity
against two different sites of AChE enzyme were identi-
fied [8]. Molecular dynamics (MD) simulations have
* Correspondence: abhinavgr@gmail.com
2School of Biotechnology, Jawaharlal Nehru University, New Delhi, India -
110067
Full list of author information is available at the end of the article
Vats et al. BMC Genomics 2015, 16(Suppl 2):S14
http://www.biomedcentral.com/qc/1471-2164/16/S2/S14
© 2015 Vats et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
further made it easier to investigate the dynamic behavior
of proteins using in silico techniques. It drastically
narrows down the investment of time, cost and effort by
limiting the number of cases for which experimental veri-
fication needs to be carried out [9]. MD simulations have
made it possible to study conformational changes that
might occur in the three dimensional structural of pro-
teins upon any change in the sequence. Therefore the
effect of mutations occurring in a protein can be eluci-
dated in detail using this computational approach. This
can further be used to investigate the mechanism that
leads to resistance of drugs in certain diseases. This
insight into the mode of action of drug with respect to
changes that occur in the three dimensional structure of
protein can then be used to design drugs effective against
both wild type and mutant isoforms of the target asso-
ciated with the disease.
Pyrazinamide (PZA), a derivative of nicotinamide is one
of the most imperative first-line drug treatments against
tuberculosis [10]. PZA is significantly used in MDR
tuberculosis in combination with isoniazid, rifampicin
and ethambutol in regimens. The most potent action of
the drug is against the semi-dormant bacilli in an acidic
environment, which cannot be treated with most other
drugs and thus helps in shortening the chemotherapy
period [11].
However, PZA is a pro-drug and acts only when meta-
bolized to pyrazonic acid (POA). Pyrazonic acid is derived
by the action of an enzyme called pyrazinamidase,
encoded by pncA gene. Mycobacterial pyrazinamidase
(MtPncA) is constitutively expressed in the cytoplasm and
plays a pivotal role in the activation of pyrazinamide[12].
Only after conversion of PZA into pyrazinoic acid by this
enzyme the drug becomes potent. The bactericidal effect
of this drug is attributed to destabilization of membrane
potential and changes in the transport function [13-15].
Emergence of drug resistant strains of tuberculosis is
one of the major concerns being faced by both developed
and developing countries. Several mutations have been
identified in Mtb proteins making them resistant to cur-
rent drug therapies. Mutations in pncA play a major role
in PZA resistance in M. tuberculosis [16-20]. The loss of
PZA activity has been attributed to non-synonymous
mutations in the gene pncA. Studies have shown that
mutations, based on their location, were able to either
decrease the activity several folds or confer resistance to
PZA [19,21-23].
Several studies have been performed to analyze the resis-
tance mechanism of the drug. One such study analyzed
three mutations namely D8G, S104R and C138Y. Study
involved analysis of binding pocket, molecular docking stu-
dies and molecular dynamics simulations. This helped in
understanding the interaction pattern of the drug with the
enzyme and three-dimensional (3D) conformational
behaviour of native and mutant PncA. The analysis pre-
dicted that the inhibition of the activity of the drug is due
to change in conformation of the enzyme. According to
the results, the binding cavity of the enzyme becomes rigid
due to these mutations, which hampers the binding of the
conversion of PZA to its active form. The major reason for
rigidity is excessive hydrogen bonding between PZA bind-
ing cavity residues and their neighboring residues [24].
The 3D-structure of PncA protein is available in PDB
(PDB ID: 3PLI). The structure was determined at a resolu-
tion of 2.2Å using PhPncA by molecular replacement [25].
The protein consists of 185 amino acid residues as
revealed by X- ray crystallography. Six stranded parallel
beta sheets and four alpha helices pack together to form
alpha/beta domain. Site directed mutagenesis based
experiments revealed Asp 8, Lys 96 and Cys138 to be the
pivotal residues involved in catalysis and Asp 49, His 57
and His 71 as the metal ion binding residues. Mutations at
these residues greatly affect the function of PncA enzyme
[19,21,25,26]. These active residues are mostly present in
the alpha- 3 helix which lies in the N-terminal region of
the protein [25].
One of the most prominent characteristic of the muta-
tions identified from the data obtained from clinical iso-
lates is their diversity. These mutations range from
missense mutations to insertions and deletions and are
spread throughout the pncA gene [16,27,28]. Since the
drug is metabolized in acidic conditions, it is cumber-
some to obtain reliable interpretation of data on resis-
tance of M. tuberculosis to the drug. Therefore, PCR
amplification and DNA sequencing of pncA is an
approach of interest as it allows rapid identification of the
pncA mutations that may be involved in PZA resistance.
This information can be used to study the correlation
between structure and function i.e. to study the effects of
mutation on the function of the enzyme. Mutational ana-
lysis thus can be used to assess PZA susceptibility.
In this study, a novel mutation Lys-96-Arg (K96R) has
been considered. This mutation was revealed by deep
sequencing via NGS (Next Generation sequencing) in the
pncA gene of 26 random Multi Drug Resistant Tuberculo-
sis patients of West African origin residing in USA. 9 out
of 26 isolates were carrying this mutation making them
resistant to pyrazinamide and in one case to all 1st and 2nd
line drugs. This mutation lies in the active center of the
protein and thereby is of utmost importance. Considering
the ratio 9/26, the mutation seems to be quite prevalent.
Since, tuberculosis is one of the most widespread disease,
counteracting the causes of drug resistance via computa-
tional studies is a good choice [29].
Here, we have tried to answer the questions recently
raised by some researches. First, what are the structural
changes produced by this mutation? Second, what is the
mechanism by which resistance to this drug develops due
Vats et al. BMC Genomics 2015, 16(Suppl 2):S14
http://www.biomedcentral.com/qc/1471-2164/16/S2/S14
Page 2 of 11
to this mutation? In the present work, we studied the
relationship between structural and physico-chemical
characteristics of PncA, with K96R mutation in the active
site, and the enzymatic function to understand PZA
resistance in M. tuberculosis. Critical understanding of
these mechanisms allows the development of robust and
efficient molecular diagnostic tests and provides a plat-
form for the development of new drugs. Further, knowl-
edge of these mechanisms can help in developing
precautionary measures to curb the development of resis-
tance [30].
In this study, we have performed several analyses to
understand the mechanism of resistance including docking
studies, binding pocket analysis and molecular dynamics
of both native and mutant PncA. The MD simulations are
known to provide the dynamic conformational changes in
the interaction of protein and ligand [31]. The results
obtained inferred that the drug resistance could be due to
the alteration in 3-D conformation of the protein by mobi-
lity of the binding residues in the mutant. The comparison
of dynamic properties of native and mutant protein was
done on the basis of molecular flexibility of the binding
residues, the network of bonds and the fluctuations
observed in them. The main objective of our work was to
understand the molecular mechanism of PncA resistance
at molecular level which causes PZA resistance in TB
patients.
Materials and methods
Structure of protein and ligand
We retrieved the native PncA protein structure (PDB:
3PL1) from Protein Data Bank (PDB) [25,32]. The pdb
structure contained a Fe2+ ion surrounded by one aspar-
tate and three histidines in the substrate binding cavity
along with three water molecules. The three most impor-
tant functional residues include Asp 8, Lys 96 and Asp
138. In order to perform further analysis the crystallized
water molecules were removed using Accelyrs Viewerlite
5.0 [33]. The 3-D structure of the drug molecule PZA was
taken from drug bank in .sdf format [34]. Since the mutant
structure was not available in the database, a point muta-
tion was introduced in silico at 96th position in the native
structure of the protein to create the mutant form.
Binding cavity analysis
The size of the binding cavity is an important measure in
mutational studies. To compare the binding cavities of
native and mutant proteins, we used CASTp server [35].
CASTp algorithm is based upon recent developments in
Computational Geometry. It has certain advantages which
include, 1) analytical identification of pockets and, 2) pre-
cisely defined boundary between solvent and pocket, and
3) calculated parameters does not make use of dot surface
or grid points and are rotationally invariant. The server
uses weighted Delaunay triangulation and alpha complex
for shape measurements. It generates information about
surface accessible pockets and interior inaccessible cavities
for a given protein. It calculates the volume and area of
each cavity in solvent accessible surface (SA, Richards’ sur-
face) and molecular surface (MS, Connolly’s surface).
Number, area and circumference of mouth pockets are
also calculated. It requires the protein .pdb structure and
the results are displayed in Jmol. We used the default
values for all the calculations using this server. A value of
1.4 Å was used as probe radius. The results were validated
using another program, MOLE 2.0 [36].
Protein ligand interaction
Receptor-ligand interaction analysis was performed for
native and mutant PncA with PZA. In order to carry
out this docking study, we used the Glide module of
Schrodinger [37,38]. The protein structure was prepared
using Schrodinger’s protein preparation wizard [39,40].
In this process hydrogen were added, bond lengths were
optimized, disulfide bonds were created, terminal resi-
dues were capped and selenomethionines were con-
verted to methionine. Flexible docking protocols were
used in which both protein and ligand were kept flex-
ible. PZA was prepared using LigPrep [41]. It generated
all possible chiral, stereochemical and ionization variants
of the ligand.
A grid was generated around the active site residues of
the protein molecule using Glide module of Schrodin-
ger. The grid was generated around Asp8, Phe13,
Asp49, His51, His57, Phe58, Gly60, Trp68, His71, Lys96,
Ile133, Ala134, Thr135, and Cys138. Extra precision
docking was then performed for native and mutant pro-
teins with PZA.
Total ligand-receptor interaction energy along with its
components like van der Waals energy and electrostatic
energy was also calculated. The electrostatic energy gives a
measure of how a molecule interacts with another nearby
molecule. The two molecules interact with each other
through their mutual electrostatic interactions. The nega-
tive value of electrostatic energy indicates better interac-
tion and vice versa. Since hydrogen bonds and van der
Waals contacts depend on complementary surfaces, these
surfaces must be able to pack closely together, creating
many contact points allowing charged atoms to make elec-
trostatic bonds. Thus, polar interactions and van der
Waals contribute to the dynamic stability of the ligand-
receptor complex [42].
The molecular docking results obtained were cross
checked using PatchDock and SwissDock [43-45].
Molecular dynamics simulations of the docked complexes
In order to investigate the mechanism of resistance in
the docked complexes, molecular dynamic study was
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performed in the presence of an explicit fully hydrated
solvent model using triclinic boundary. The simulations
were performed using Desmond Molecular Dynamics
module of Schrodinger, with Optimized Potentials for
Liquid Simulations (OPLS) all-atom force field 2005
[46,47]. The complexes were prepared before simulation
by addition of hydrogen atoms followed by optimization,
capping of end terminals, conversion of selenomethio-
nine to methionine and generation of disulphide bonds
using the protein preparation wizard. Prepared protein-
ligand complexes were then solvated with SPC water
model in a triclinic periodic boundary box. To prevent
interaction of the protein complex with its own periodic
image, the distance between the complex and the box
wall was kept 10 Å. Energy of the prepared systems was
minimized for 5000 steps using steepest descent method or
until a gradient threshold of 25kcal/mol/Å was achieved. It
was followed by L-BFGS (Low-memory Broyden- Fletcher-
Goldfarb Shanno quasi-Newtonian minimiser) until a con-
vergence threshold of 1 kcal/mol/Å was met. For system
equilibration, the default parameters in Desmond were
applied. The equilibrated systems were then used for simu-
lations at a temperature of 300 K and a constant pressure
of 1atm, with a time step of 2fs. For handling long range
electrostatic interactions Smooth Particle Mesh Ewald
method was used whereas Cutoff method was selected to
define the short range electrostatic interactions. A cut-off
of 9 Å radius was used.
Results and discussion
Continuous emergence of new mutations associated with
drug resistance in Mycobacterium tuberculosis is posing a
great danger to the conventional therapies. The methods
need to be revised according to the current situation,
which requires understanding of the mechanisms of
resistance. In order to identify one such mechanism we
have tried to analyze the mutation K96R occurring in the
active site of Mycobacterium tuberculosis. Various ana-
lyses have been done in order to understand the mechan-
ism at molecular level.
Preparation of mutant protein
Since the structure of mutant protein was not available in
the database, in silico mutation was created at position 96
by replacing lysine with arginine. In order to allow the
protein to rearrange the backbone and the side chains of
the mutated residue and the nearby amino acids so as to
reach the conformational state with no steric clashes and
minimum internal energy, it was subjected to MD simu-
lation for 15 ns. RMSD of each frame in reference to the
first frame was plotted against the simulation time to
comment on the equilibrium state of the mutated pro-
tein. Initially an RMSD of 4Å was observed for the first
6 ns after which an almost stable trajectory was obtained.
The coordinates of all the frames within the most stable
time frame, i.e. from 6 to 15 ns, were averaged to com-
pute a structure representing the equilibrated state of the
mutated protein. This representative average structure
was used for further study.
Binding cavity analysis
Binding pocket analysis is an important measure to iden-
tify the impact of mutation on the cavity. The pocket
volume for both native and wild type were calculated
using CASTp server. The structures obtained after mole-
cular dynamics were used for the calculation of the pocket
volume. The volume of the cavity for native PncA protein
was 551.9 Å3 and that of mutated form was 1314.2 Å3.
A considerable difference can be seen in the two volumes
(Figure 1). The increase in volume affects the binding of
PZA within active cavity thereby decreasing the stability of
the ligand. In order to further evaluate the behavior of the
mutant, we performed docking and molecular dynamics
simulation studies.
The change in the cavity size was further validated
using MOLE 2.0. A significant increase in the active site
volume was observed for the mutant protein with this
program as well.
Interaction analysis between receptor and ligand
molecule
Previous studies on PncA have shown the significance of
van der Waals interactions in binding to PZA. Binding
energy calculations provide information on both van der
Waals and electrostatic energy of the complex. The value
of van der Waals energy and electrostatic energy for
native complex calculated using Glide was found to be
-17.16 kcal/mol and -10.27 kcal/mol respectively. The
glide energy or the total ligand-receptor energy was
found to be -27.43 kcal/mol for the native PncA and
PZA complex. On the contrary, there was a significant
difference in the values for the complex with mutated
protein. The values for van der Waals, electrostatic and
glide energy were -10.86, -13 and -23.43 kcal/mol respec-
tively (Table 1). As indicated by the total energy, PZA in
complex with mutated PncA was less stable in compari-
son to PZA docked with native PncA. Hydrogen and
hydrophobic interactions also play a major role in mak-
ing the binding stable. The interaction plots for these two
types of interactions were generated using Ligplot [48].
In native complex, an oxygen atom of PZA was found
making one hydrogen bond with the nitrogen of Ala 134
of PncA and the distance was 3.19Å (Figure 2A). The
ligand also made a significant number of hydrophobic
bonds with Asp 8, Phe 13, leu1 9, Val 21, Ile 133, His 137,
Cys 138 and Val 163 of PncA (Figure 3A). On the other
hand the mutant protein was found to be making two
hydrogen bonds. An oxygen atom of the ligand was
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making hydrogen bonds with nitrogen of Ala 134 and Cys
138 of mutated protein and the bond lengths were 3.11 Å
and 3.08 Å respectively (Figure 2C). However, the number
of residues involved in making hydrophobic contacts was
less in the case of mutated protein-PZA complex. Amino
acids of mutated PncA participating in hydrophobic inter-
actions included Asp 8, Gln 10, Ile 133 and His 137
(Figure 3C). We observed a difference in the interaction
pattern of the two proteins with PZA. Cys 138, one of the
key active residues was involved in hydrophobic interac-
tion in native protein complex while in mutant complex it
was forming a hydrogen bond with the ligand. Over all,
PZA had a lower binding affinity towards the mutated
form of PncA as indicated by the docking score of -3.77 in
comparison to the wild type protein, with which it had a
glide docking score of -4.025. To further validate the bind-
ing affinity two online servers, PatchDock and SwissDock
were also used. The results obtained indicated a lower affi-
nity of PZA for the mutated protein in comparison to the
wild type. It was in coherence with the results obtained
using Glide.
All the three factors, namely, volume of binding
pocket, docking score and interaction energy, typically
used here to explain the reason for resistance to drug
Figure 1 Ribbon representation of the superimposition of structures of the native and mutant M. tuberculosis PncA protein.









Native -4.025 -27.43 -17.16 -17.16
Mutant -3.77 -23.434 -13.0 -10.86
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supported the idea of weak binding of the ligand with
the protein in mutated form, which was hampering its
activation. However, increased number of hydrogen
bonds in mutant complex was suspicious. Therefore, in
order to study the conformational changes occurring in
the complexes in dynamic environment similar to in
vivo conditions, we performed molecular dynamics
simulation studies. Calculation and analysis of para-
meters like RMSD, radius of gyration and RMSF was
done to understand the behavior of binding of the
ligand with the enzyme.
Investigation of flexibility of native and mutant PncA
enzyme
PZA bound native and mutant proteins were simulated
in a SPC water box for around 15 ns. RMSD trajectory
was analyzed for both the complexed systems. As shown
in Figure 4, the native unbound and native protein com-
plex, both were quite stable. The native unbound display
low fluctuations and remain stable throughout the simu-
lations. The native bound also did not deviate much from
its initial docked conformation. However, in the mutant
structure, the protein complex showed deviation up to
3Å in the first half phase of the simulation run and then
gave a stable RMSD trajectory (Figure 4).
Some changes were observed in the interaction pat-
tern of the native and mutant complexes post molecular
dynamics studies. In native complex, the number of
hydrogen bonds increased to two. The oxygen atom of
PZA was making two hydrogen bonds with nitrogen of
Ala 134 and Cys 138 with bond lengths of 3.33Å and
2.89Å respectively (Figure 2B). The hydrophobic interac-
tions however reduced. PZA was now making hydro-
phobic contacts with Asp 8, Phe 13, Val 21, Ile 133 and
His 137 of native PncA (Figure 3B). On the other hand,
mutant complex was now making only one hydrogen
bond with Ala 134 (Figure 2D). The bond length for the
corresponding hydrogen bond was observed to be
Figure 2 Depiction of hydrogen bond interactions in A) native protein bound to PZA after docking, B) native protein bound with PZA
after MD simulations, C) docked mutant PncA-PZA complex, D) mutant protein bound to PZA post MD simulations.
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3.06Å. Seven amino acid residues of mutant proteins,
namely Asp 8, Gln 10, Phe 13, Asp 49, Ile 133, His 137
and Cys 138 were now interacting hydrophobically with
PZA (Figure 3D).
The radius of gyration is defined as the mass-weighted
root mean-square distance of a cluster of atoms from
their common center of mass. In other words, the radius
of gyration of a protein is a measure of its compactness.
A protein will maintain a steady value of Rg if it is stably
folded, and the value will fluctuate if the protein unfolds.
The radius of gyration of all the frames during the simu-
lation run was plotted against time and the data was ana-
lyzed. The curve for the native complex was stable
throughout the simulation period and fluctuations were
negligible. This steady curve can be attributed to high
stability and compactness of the protein. The plot for the
mutant protein complex was however more fluctuating
and the value for Rg reached as high as 17 Å (Figure 5).
This fluctuation was prevalent during the entire simula-
tion period. Hence it can be inferred that the protein
was losing its compactness due to the change in its
conformation.
Root mean square fluctuation (RMSF) with respect to
each residue in both native and mutant complex was then
calculated to explain the loosening of the mutant protein
structure. The fluctuations were widespread in the mutant
protein, while in native sequence small fluctuations were
observed in certain regions. The fluctuations in certain
residues of native protein were conferring flexibility to the
protein and keeping it compact at the same time. While in
case of mutant protein, high level of fluctuations depicting
high mobility of the residues was resulting in a loosely
Figure 3 Hydrophobic interaction pattern in A) native protein bound to PZA after docking, B) native protein bound with PZA after
MD simulations, C) docked mutant PncA-PZA complex, D) mutant protein bound to PZA post MD simulations.
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packed protein. As illustrated in Figure 6, fluctuations
were highest in the loop region i.e. from 51 to 71 amino
acid residues. This result was in accordance with informa-
tion obtained from superposition shown in Figure 1. The
loop region of the mutated protein moved away from the
active cleft, which was also the reason behind increase in
the volume of catalytic cavity. According to a study, resi-
dues 51 to 71 compose an important loop region or a flap
which is involved in holding the ligand in position after
binding. Thus this loosening of the loop region was affect-
ing the binding of PZA with the active residues.
The RMSF of catalytically important binding residues,
Asp 8, Phe13, IIe133, Ala134 and Cys138 of native and
mutant structures were also analyzed. Table 2 lists the
RMSF values of all these residues in unbound mutant,
mutant and native protein bound with PZA. The fluc-
tuation in binding residues was very small in case of
native protein while these residues were highly flexible
in case of mutant protein in both bound and unbound
form.
All these analyses brought the discussion to the point
that in mutated form the flap region of the protein
becomes more flexible and moves away from the active
site. This results in a much bigger active cavity. Once
the ligand, PZA comes and binds to the active residues,
flap is not able to hold it in bound state thereby pre-
venting the activation of the prodrug.
Previously studies have been performed on PncA
mutations namely, D8G, S104R and C138Y. The analysis
showed that the binding cavity volume decreased and
the cavity became rigid. This did not permit proper
alignment of PZA inside the cavity and hampered
hydrogen bond formation. Our study included a novel
mutation. The mutation being present in the flap region,
Figure 4 Graph showing the RMSD of backbone of native unbound protein, native bound to PZA, mutant protein in unbound form
and mutant protein in complex with PZA.
Figure 5 Radius of gyration of native and mutant protein in complex with PZA.
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affected the volume of the cavity in contrast to the pre-
vious mutations. The mutation led to a substantial
increase in the binding cavity. This prohibited the
enzyme from holding the drug properly and therefore
PZA could not take its active form [24].
Conclusion
This study is intended to present a comprehensive analysis
of the drug resistance mechanism caused by K96R muta-
tion in PncA enzyme of M. tuberculosis. Here we have
performed binding pocket analysis, molecular docking and
molecular dynamics simulation studies. The binding cavity
analysis showed a significant increase in the volume of the
active cavity from 551.9 to 1314.2 Å3 upon mutation. This
fact was further supported by RMSF, radius of gyration
and simulations studies. We showed that the flap region
becomes highly flexible in mutated protein and moves
away from the active cavity and is no longer able to hold
the bound drug in its place. This prevents the activation of
the prodrug to this functional form. And hence the patient
with this K96R mutation develops resistance to PZA drug.
This study gives insight into the mechanism by which
drug resistance is acquired and therefore can be helpful
while designing new drugs for tuberculosis treatment.
Using the analysis, new classes of drugs can be produced
which have a better conformation such that the binding to
important residues is not affected by the changing
volumes. Ligands should possess functional groups which
permit the establishment of strongly interacting hydrogen
bonds with the binding residues.
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